Dallas, TX: ReportsandReports announce it will carry Novartis AG: PharmaVitae Profile Market Research Report in its Store.
Browse complete Novartis AG: PharmaVitae Profile Report
Introduction
This analysis examines the historical and forecast performance for Novartis in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
- Benchmark Novartis’s performance against key rivals in the prescription pharmaceutical sector
- Assess Novartis’s strategy of diversification from the typical Big Pharma growth model, including its movement into the generics market via Sandoz
Table of Content
ABOUT DATAMONITOR HEALTHCARE
About the PharmaVitae team
Chapter 1 About this profile
PharmaVitae Explorer database
Chapter structure
Executive summary
Quarterly update
Company introduction
Company sales
Company financials
Key products
Data sourcing
Sales data
Analyst consensus
Chapter 2 Executive summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003-15
Financial performance, 2003-15
Novartis: PharmaVitae forecasts at a glance
Strategic insight
Novartis is forecast to deliver strongest organic growth within Big Pharma 2009-15
Diversified prescription pharma offering integral to sales growth performance
Exposure to generic competition will blunt branded pharmaceutical sales growth
Evolution of vaccine offering will drive steady revenue growth
Sandoz poised to exploit diverse segments of global generics market
Further diversification to be driven by Alcon acquisition
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
Table of Contents
Table of figures
Chapter 3 Quarterly update
Latest quarterly sales
Latest comment
Q2 2010
Novartis: blockbuster revenues beckon for multiple sclerosis pill
Lucentis shows potential in diabetic macular edema
AAN 2010: spotlight shines on Novartis’ and Merck KGaA’s oral MS candidates
Q1 2010
Novartis: Debiopharm deal strengthens hepatitis C pipeline
Novartis: Fanapt marks weak return to competitive antipsychotics market
Novartis eyes Alcon merger
Q4 2009
ASH 2009: Novartis looks to position Tasigna as an alternative to Gleevec in CML
Q2 2009
Novartis: Afinitor boasts considerable commercial potential
Q1 2009
Novartis: Extavia launch provides foothold in MS market
Latest prescription pharma product news
Q2 2010
Q1 2010
Q4 2009
Q3 2009
Q2 2009
Q1 2009
Latest corporate news
Q2 2010
Q1 2010
Q4 2009
Q3 2009
Q2 2009
Q1 2009
Chapter 4 Company introduction
Key findings
Background
Key corporate developments
M&A history
Push into generics market
Sandoz
Movement into vaccines/diagnostics
Chiron
Alcon deal demonstrates further diversification
One eye on Alcon: a strong fit with Novartis Ophthalmics
Recent M&A in branded prescription segment
Chapter 5 Company sales
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003-15
Product analysis
Product analysis, 2003-09
Product analysis, 2009-15
Product analysis, 2009-15
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2009-15
Core analysis, 2009-15
Expiry analysis, 2009-15
Generics analysis, 2009-15
Launch/core/expiry configuration, 2009-15
Molecule type analysis
Externalization analysis
Chapter 6 Company financials
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003-09
Operating costs and profit analysis
Operating costs and profit analysis, 2003-09
Operating cost ratio and profit margin analysis, 2003-09
Operating cost ratio and profit margin analysis, 2009-15
Operating costs and profit analysis, 2009-15
Chapter 7 Key products
Overview
Glivec/Gleevec
Summary
Sales forecast
Gilenia
Summary
Sales forecast
QMF149
Summary
Sales forecast
QVA149
Summary
Sales forecast
Tasigna
Summary
Sales forecast
Diovan/Co-Diovan
Summary
Sales forecast
Co-Diovan
Summary
Sales forecast
Zometa (includes Aclasta/Reclast)
Summary
Sales forecast
Femara
Summary
Sales forecast
Sandostatin
Summary
Sales forecast
Chapter 8 Appendix
References
Abbreviations
Exchange rates
About Datamonitor
About Datamonitor Healthcare
Datamonitor consulting
Disclaimer
Browse complete Novartis AG: PharmaVitae Profile Report
Browse all Healthcare Market Research Reports
Browse all Datamonitor Market Research Reports RSS
Browse all Latest Report
Related Reports:
Novartis AG-Detailed Product Pipeline
Novartis AG-Deals & Alliances Report
Novartis AG-Therapeutic Competitors
About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/
